Pasado, presente y futuro de la vacunación anti-idiotipo
Keywords: 
Inmunoterapia
Mieloma múltiple
Vacuna
Idiotipo
Linfoma
Issue Date: 
2004
Publisher: 
Ediciones Universidad de Navarra
ISSN: 
0556-6177
Citation: 
Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, et al. Pasado, presente y futuro de la vacunación anti-idiotipo. Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23.
Abstract
Cancer vaccines are conceived as therapeutic tools, in contrast to the prophylactic vaccines used to fight against infectious diseases. Among the most potent therapeutic vaccines, anti-idiotype vaccination is directed against the tumor idiotype, the only well-characterized tumor antigen displayed in neoplastic B-cells. Anti-idiotype vaccines have demonstrated clinical benefit against follicular lymphoma and are currently being evaluated in two different phase III clinical trials. Additional emerging strategies, which include the use of dendritic cells and the production of vaccines via molecular means will surely allow us to draw important conclusions concerning the treatment of cancer patients.

Files in This Item:
File: 
Rev Med pasado pag 14-23.pdf
Description: 
Size: 
322,01 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.